Results 171 to 180 of about 51,607 (296)

High‐dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited‐stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial

HemaSphere, Volume 9, Issue 4, April 2025.
Gotti Manuel, Yana Stepanishyna, Tetiana Skrypets, Luigi Marcheselli, Caterina Cristinelli, Barbara Botto, Sanne Tonino, Doriane Cavalieri, Alessandro Pulsoni, Martin Hutchings, Mohammad Hammoud, Catherine Fortpied, Luigi Rigacci, Wouter Plattel, Marc André, Massimo Federico   +15 more
wiley   +1 more source

Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen

European Journal of Haematology, Volume 114, Issue 4, Page 626-635, April 2025.
ABSTRACT Venetoclax with hypomethylating agents (HMA) is the standard of care for acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy and is associated with tumor lysis syndrome (TLS). TLS prophylaxis and the use of Cairo Bishop versus Howard diagnostic criteria are not standardized.
Margaret Rowe, Daria Babushok, Martin Carroll, Alison Carulli, Noelle Frey, Saar Gill, Elizabeth Hexner, Rebecca Hirsh, Nasheed Hossain, Catherine Lai, Alison Loren, Selina Luger, Ivan Maillard, Shannon McCurdy, Andrew Matthews, Mary Ellen Martin, Vikram R Paralkar, Alexander Perl, David Porter, Keith Pratz, Edward Stadtmauer, Ximena Jordan Bruno   +21 more
wiley   +1 more source

Autologous peripheral blood progenitor cell transplantation mobilized with high-dose cytarabine in acute myeloid leukemia in first complete remission

, 1998
S Pavlovsky, Isolda Fernández, Giuseppe Milone, Juliana Martínez Rolón, Claudia Corrado, Pablo Desmery, Cecilia Dignani, M. Michelet, Mariana Juni   +8 more
openalex   +1 more source

Cytarabine-induced acute generalized exanthematous pustulosis [PDF]

, 2002
Annie Chiu, Sabine Köhler, Joseph McGuire, Alexa B. Kimball   +3 more
openalex   +1 more source

Post‐Relapse Outcomes of Older Patients With NPM1‐Mutated AML Are Favorable With Allo Transplant in Second Remission

European Journal of Haematology, Volume 114, Issue 4, Page 641-649, April 2025.
ABSTRACT Molecular assessment of measurable residual disease (MRD) in NPM1‐mutated AML patients is a powerful prognostic tool to identify the risk of relapse. There is limited data regarding MRD‐guided decisions against alloSCT in elderly patients and FLT3–ITD co‐mutation.
Avraham Frisch, Chezi Ganzel, Yishai Ofran, Baher Krayem, Arnon Haran, Vladimir Vainstein, Shlomzion Aumann, Noa Gross Even‐Zohar, Boaz Nachmias   +8 more
wiley   +1 more source

Corneal epithelial microcysts due to high dose Cytarabine administration in acute myeloid leukemia

Turkish Journal of Hematology, 2012
Tuba Hilkay Karapınar, Salih Gözmen, Özlem Tüfekçi, Şebnem Yılmaz, Zeynep Özbek, Melih Parlak, Gülersu İrken, Hale Ören   +7 more
doaj   +1 more source

Magnetic Resonance Imaging Findings in a Case of Cytarabine-Induced Myelopathy [PDF]

, 2002
Paul M. Sherman, Clifford J. Belden, Douglas A. Nelson   +2 more
openalex   +1 more source

Advances and Challenges in Quizartinib‐Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies

European Journal of Haematology, Volume 114, Issue 4, Page 584-595, April 2025.
ABSTRACT FLT3 mutations are among the most common genetic alterations in acute myeloid leukemia (AML) and are associated with poor prognosis. Significant advancements have been made in developing FLT3 inhibitors (FLT3Is), such as quizartinib, which have improved treatment outcomes in both newly diagnosed and relapsed/refractory AML.
Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Teresa Rossi, Antonino Neri, Fortunato Morabito, Ernesto Vigna, Massimo Gentile   +10 more
wiley   +1 more source

Is age just a number? Intensive therapy for core-binding factor acute myeloid leukemia in older adults. [PDF]

Haematologica
George BM, Luskin MR.
europepmc   +1 more source

Plasma Concentration of Cytosine Arabinoside (Ara-C) in the Eldery Patients with Hematological Malignancy Treated by Ara-C or Cytarabine Ocfosfate (SPAC).

, 1995
Hiroyuki Tsutsumi, T Kumakawa, Masami Yokota Hirai, Masayuki Kikukawa, Y. Ben Arie, Mayumi Mori, H Kodo, N. Nakamura, Y Murai, Ryuta Mizutani   +9 more
openalex   +2 more sources